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Type C RNA tumor viral  (oncornavirus) genetic information,  viral proteins, 
and intact virions have been detected in malignant tissues from many species of 
animals including cats, chickens, and mice by biochemical, immunological, and 
ultrastructural techniques (1-3). Hallmarks of the presence of RNA tumor virus 
genomes have  also been found in human  malignant  tissues.  These indicators 
include  cellular  nucleic  acid  sequences homologous to  those  of oncornavirus 
RNA (4, 5), RNA-dependent DNA polymerase (reverse transcriptase) function- 
ally (6, 7) and antigenically (8) related to oncornavirus transcriptase,  intracellu- 
lar  proteins  reactive  with  antisera  against  oncornaviral  proteins  (9-12),  and 
intracellular virus-like particles (13).  Oncornaviral genetic information or pro- 
teins have also been found in normal cells from a variety of species (1), and some 
evidence suggests that this is also true of human cells (9,  14). C-type particles 
have been found in normal human placentas (15). Furthermore, oncornaviruses 
can productively infect human cells (16,  17) and under certain conditions trans- 
form such cells (18). These observations tend to suggest a major role for C-type 
oncornaviruses in human leukemias.  However, viremia is not a  characteristic 
feature  of human  leukemia  in  contrast to leukemias  of other animals  (1,  2). 
Although  oncornaviruses  can  be  antigenic  in  man  (19),  antibodies  to  viral 
antigens have only infrequently been found in the sera of patients with leuke- 
mias (20-22), yet circulating antibody is a common feature ofleukemias in other 
animals (1, 21, 23, 24). Recently oncornaviruses have been isolated from cultures 
of human leukemic tissues in several laboratories (25-27), but the long history of 
earlier failures (13, 28) indicates that expression of intact oncornaviruses is not a 
prominent feature of human leukemias. Taken together,  these studies indicate 
that some oncornaviral genetic information is present in human leukemic and 
perhaps normal  cells but this information  is not reflected in the production of 
oncornaviral antigens or particles. In seeking an explanation for this apparent 
failure of extracellular expression, we found that normal human serum, but not 
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chicken, guinea pig, rabbit, rat, or most murine sera, had the ability to inacti- 
vate a number of oncornaviruses from avian, feline, murine, and simian sources 
as measured either by plaque or focus reduction assays (29, 30). The mechanism 
of inactivation  was by viral lysis since the internal  enzyme,  RNA-dependent 
DNA polymerase (RDDP) 1 and also viral RNA were released after incubation of 
oncornaviruses with primate but not with nonprimate  sera.  Inactivation  was 
complement  (C)-dependent  as heated human sera and C2-  or C4-deficient hu- 
man sera did not produce viral lysis. We were unable to find a role for antibody 
in this process (29,  30). 
We report here an analysis of the mechanism of action of the C system in the 
inactivation process. These studies show that the Clq subunit of the first human 
C  component  subserves  a  specific  recognition  function  which enables  the  C 
system to act as a  natural  defense mechanism against  oncornavirus infection 
and  replication  in  man.  Human  Clq  attaches  directly  to  the  oncornavirus 
envelope  in  the  absence  of immunoglobulin.  Binding  of C1  via  Clq  in  this 
manner leads to activation of C1 and thus of the classical C pathway, accompa- 
nied by deposition of C components on the viral surface and lysis on completion 
of the C sequence. 
Materials and Methods 
Chemicals and Reagents.  Sodium barbital and Tris (Sigma Chemical Co., St. Louis, Mo.) were 
used  to prepare  buffers.  DNase  I  and  RNase  were  purchased  from  Worthington  Biochemical 
Corp., Freehold, N. J. 
C, Components,  and C Reagents.  Fresh serum frozen in portions at -70°C was employed as a 
source of C. Human Clq was isolated from fresh serum by the method of Yonemasu and Stroud (31) 
and  homogeneity verified by sodium  dodecyl sulfate polyacrylamide gel electrophoresis  (SDS- 
PAGE). Preparations of Clq employed in this study showed no IgG, IgA, or IgM when tested with 
appropriate antisera (Behring Diagnostics, American Hoechst Corp., Somerville, N. J.) in Ouch- 
terlony analyses. Proenzyme Clr (32), proenzyme Cls (33), C2 (34), C4 (35), and factor B (36) were 
isolated from fresh human serum by using the published methods.  The cellular intermediates, 
EAC1, EAC14, and EAC1423 were prepared with human components as previously described (34, 
37). 
Human serum genetically deficient in C2 was obtained from patient T. H. (38) and CS-deficient 
human  serum from an individual homozygous for C8 deficiency (39). Fresh human  serum was 
depleted of C4 or factor B by addition of 1 × 10  -2 M EDTA and passage through an agarose column 
containing the IgG fraction of antiserum  to the appropriate  protein coupled to CNBr-activated 
Sepharose 4B (Pharmacia Fine Chemicals, Inc., Piscataway,  N. J.). After separation,  sera were 
concentrated to their original volume and dialyzed against veronal-buffered NaC1 containing 1.5 
x  10 -4 M calcium and 5  ×  10 -4 M magnesium and stored in aliquots at -70°C. For some studies 
factor B was depleted by heating at 50°C for 20 min. The absence of each respective protein was 
verified by Ouchterlony analyses. Measurements of functional activity of the depleted component 
showed less than 1% of the original activity. The C2-, C4-, and C8-depleted sera employed in this 
study could be restored to full CHso (dilution of normal serum giving 50% lysis of sheep erythro- 
cytes sensitized with  IgM rabbit  antiserum)  activity by addition of the missing component  in 
highly purified  form,  usually  together  with  Clq.  These  sera  possessed  an  intact  alternative 
Abbreviations  used in this paper: CHso, the dilution of normal serum giving 50% lysis of EA; 
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pathway as evidenced by their ability to sustain C3 cleavage after the addition of inulin (39). The 
factor B.depleted serum used could be reconstituted by isolated factor B with regard to C3 cleavage 
after inulin addition; the classical pathway was essentially intact in these sera since the CHso 
values were approximately 50% of normal, 
Viruses and Labeling.  Most of the viruses employed in this study and their cellular origins 
and methods of propagation have been described (30). In addition primate Rauscher leukemia 
virus (PRLV) propagated in rhesus embryonic monkey cells (40), Moloney leukemia virus (MLV) 
obtained from the NCI, and MLV isolated from SCRF 179 murine tymphoblasts (MLV-179S) and 
MLV  from  murine  NIH-Swiss 3T3  fibroblasts (MLV-FAN) were used for some experiments. 
Xenotropic murine leukemia virus was isolated from testes of New Zealand Black mice by co- 
cultivation with rabbit SIRC cells. 
Viruses were obtained from filtered supernatant fluids by sedimentation through a layer of 15% 
sucrose (wt/vol) onto a  cushion of 50% sucrose (wt/vol). Centrifugation was for 60 rain at 25,000 
rpm (105,000 g) in a Beckman SW 25 Rotor (Beckman Instruments, Inc., Spinco Div., Palo Alto, 
Calif.). This step was repeated after which the virus was purified by isopycnic sedimentation in a 
15-50% (wt/vol) sucrose density gradient. Centrifugation was for 16 h at 35,000 rpm (155,000g) in a 
Beckman SW 41 Rotor in a  1 ×  10 -2 M Tris, 1 ×  10 -~ M NaC1,  1 x  10 -3 M EDTA buffer, pH 7.5, 
(STE). 
The  RNA  of rat  leukemia  virus  was  labeled by  propagating  infected Brown  Norway  rat 
fibroblasts in the presence of ~H-uridine  (10  ~Ci/ml)  for 21  h.  Labeled virus was purified as 
described above. MLV was externally labeled with ~5I by incubation of 0.1 ml of purified virus 
with 0.5 mCi of carrier-free Na ~s~I (50 mCi/ml, New England Nuclear, Boston, Mass.), 1 mg of 
human serum albumin, and 50 ~g of lactoperoxidase (Calbiochem, San Diego, Calif.) in a total vol 
of 150 ~tl for 10 min at room temperature. During this time two additions of 25 ~l of 0.03%  H202 
were made. The mixture was then layered over a  20-65%  sucrose density gradient in 1 ×  10  -2 M 
Tris, 1 × 10 -~ M NaC1 buffer, pH 7.5, containing 10 mg/ml human serum albumin and centrifuged 
at 50,000 rpm for 60 rain in a Beckman SW 50 rotor. Under these conditions the radiolabeled virus 
formed a discrete peak of radioactivity in the center of the gradient. 
Sucrose Density Gradient Ultracentrifugation.  C-mediated release of 3H-RNA from MLV was 
examined by equilibrium sedimentation. MLV, internally labeled with ~H-uridine, was reacted 
with an equal volume of serum or serum derivatives for 30 rain at 37°C and then layered over a 15- 
50% (wt/vol) continuous sucrose density gradient in STE buffer and centrifuged for 16 h at 35,000 
rpm in an SW 41 Rotor. The gradients were fractionated and the refractive index of each fraction 
was determined in  a  Bausch &  Lomb refractometer (Bausch &  Lomb Inc.,  Scientific Optical 
Products Div., Rochester, N. Y.). The radioactive counts were determined after the addition of 
Aquasol (New England Nuclear) containing acetic acid and water in a Beckman liquid scintilla- 
tion system. 
The  interaction of ~I-MLV with serum or serum derivatives was examined by  rate  zonal 
sucrose density gradient sedimentation. Equal volumes of ~2~I-MLV and serum or derivatives were 
incubated for 30 min at 37°C after which the mixtures were layered over 20-65%  (wt/vol) sucrose 
density gradients formed in a  5  x  10 -2 M Tris, 1 ×  10 -~ M NaC1 buffer, pH 7.5.  Centrifugation 
lasted for 60  min at 50,000  rpm in a  Beckman SW 50.1  Rotor. Afterward the gradients were 
fractionated, and radioactivity was determined in a Beckman Biogamma II spectrometer. In some 
experiments a pool of fractions comprising the peak of radioactivity was incubated with the IgG 
fraction of antiserum to C4 for 30 rain at 37°C and re-examined in a second identical rate zonal 
sucrose density gradient separation. 
Binding of Clq to MLV was examined by incubating 125I-Clq (approximately 1 ~g) with MLV 
for 30 rain at 37°C in a 5 × 10 -2 M Tris, 1 ×  10 -L M NaC1 buffer, pH 7.5, adjusted to 7 mmho/cm at 
22~C by addition of sucrose containing barbital buffer, pH 7.5. The mixtures were then layered 
over 20-65%  (wt/vol) sucrose density gradients and processed as described above. 
Clq Deviation  Test.  This test was performed as previously described (41) with certain modifi- 
cations in the buffer to compensate for the lack of serum. 10 ~1 of ~sI-Clq (1  pg) were incubated 
with varying amounts of MLV in a total vol of 0.25 ml in a barbital-buffered, NaCl, and sucrose 
containing buffer, pH 7.5, having a conductance of 9 mmho/cm (41). After incubation for 20 rain at 
room temperature, 0.2 ml of the same buffer containing 4 × l0  s sheep erythrocytes (E) coated with 
rabbit IgG anti-sheep E  (EA) were added and incubation continued for i0 min at room tempera- 
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sucrose cushion in a Beckman microfuge tube. After centrifugation in a Beckman Microfuge for 5 
min,  the  tubes  were  clamped  and  sectioned,  and  the  radioactivity  present  in  the  pellet  and 
supernate determined separately. Results were expressed as the percent of radioactivity bound to 
EA. 
Radiolabeling ofProenzyme Cls.  Isolated Cls was radiolabeled by the chloramine-T method 
(42). 
RDDP Release Assay.  Fresh serum or serum derivatives were mixed with an equal volume of 
virus and incubated for 30 minutes at 37°C. An equal volume of an assay mixture was then added 
and incubation continued for 30 minutes at 37°C. The RDDP assay mixture contained the following 
ingredients:  1.5  mM  MgC12; 0.05  M  Tris  buffer,  pH  8.1;  20  mM  dithiothreitol  (DTT);  100  ftM 
deoxyadenosine 5'-triphosphate;  100 ~M deoxycytidine 5'-triphosphate;  100 ~M deoxyguanosine 
5'-triphosphate; 10 /~g/ml poly(rA)-oligo(dT)~2_ls,  (P-L Biochemicals, Inc., Milwaukee,  Wis.); and 
100 ~Ci/ml (2.5 mM) [methyl-3H]thymidine 5'-triphosphate (New England Nuclear, sp act 50 Ci/ 
mmol). Nonidet P-40 (NP-40) (Shell Chemical Co., New York) (0.03-0.1% final concentration) was 
added to the virus in place of serum for maximum lysis,  and  a  requirement for the pely(rA)- 
oligo(dT) template was assessed during the assays by running duplicate reactions in the absence of 
that  synthetic  polymer.  After  the  incubation,  pelymerized  radioactivity  (3H-deoxythymidine 
monophosphate  [TMP])  was quantitated  by spotting the samples on DEAE-cellulose filters and 
washing  the  filters  with  5%  Na2HPO4,  water,  ethanol,  and  ether.  Samples  were  counted  in 
Aquasel using a Beckman liquid scintillation system. 
PAGE.  Analyses were performed in 7% polyacrylamide gels containing 0.1% SDS in phos- 
phate buffer, pH 7.25, by using a modification (32) of the method of Weber and Osborn (43). One 
volume of reaction mixture was mixed with one volume of phosphate buffer containing 8.5 M urea, 
2% SDS, and 1.4  ×  10  -2 M DTT. After boiling for 5 rain, an equal volume of 50% glycerol in water 
saturated  with bromophenol blue was added and 25-~l samples were applied to 5  ×  80 mm gel 
columns  and  electrophoresis  carried  out  for  3  h  at  8  mA/gel in  a  Hoefer gel electrophoresis 
apparatus (Hoefer Scientific Instruments, San Francisco, Calif.) (32). The gels were then sectioned 
at  2-mm  intervals  and  the  segments  analyzed  for radioactivity  in  a  Beckman  Biogamma  II 
Spectrometer. 
Measurement of CH~o and C Component Hemolytic Activity.  Fresh human serum was incu- 
bated with an equal volume, usually 0.2 ml, of various concentrations of isolated MLV for 60 rain 
at 37°C. Subsequently, residual C activity was determined by CH~o titration (44) and residual C1 
(32), C2 (34), C3 (45), C4 (36), C5 (45), C8 (46), and C9 (46) activities were quantitated by effective 
molecular titration  according to  the  published  methods.  Consumption  of more than  15%  was 
considered to be significant. 
Measurement of C1  Activation.  Proenzyme  C1  was  reconstituted  by  10  pg each of highly 
purified,  immunoglobulin-free human  Clq, human  proenzyme Clr,  and  12~I-human  proenzyme 
Cls  in  a  total  vol  of  60/~l  in  a 5 x i0  -2  M Tris,  1 x I0-;  M NaCl  buffer,  pH 7.5  containing  5 x 10  -3  M 
CaCI2. After formation of C1 for 10 rnin  at 22°C,  5-/~I  samples of the reaction mixture were 
incubated with 15-30 pg of  MLV  in  a vol of  25 pl. Incubation continued for  30  rain  at  30°C,  after 
which SDS, urea,  and DTT were added and electrophoresis  was performed as described above. 
Controls always included Clr and Cls incubated together  with the various virus  preparations in 
the absence of  Clq. Also included in each run were 5-~I  samples of  C1 incubated with 25 ~l of 
buffer  and with 25 ~l of  buffer  containing 30 ~g of  aggregated  human IgG (63°C,  15 rain). 
Results 
C Requirements  for  Viral  Lysis.  Previously,  we  had  found  that  fresh  human 
serum released  RDDP  from multiple oncornaviruses including  feline  leukemia 
virus,  MLV, and RLV  (29).  However, heated human serum, C2-deficient  and 
C4-depleted  human sera  were unable to release  RDDP  from these viruses  (29). 
Identical  results  have since  been obtained with  other  oncornaviruses,  including 
AKR  routine  leukemia virus (MuLV), rat leukemia virus (RaLV), and the 
xenotropic  MuLV. Data for the latter  virus  are shown in Table I, which also 
indicates  that completion of  the C reaction  sequence is  probably required since 
C8-depleted  serum did not mediate lysis. 974  COMPLEMENT  LYSIS  OF  RNA  TUMOR  VIRUSES 
TABLE  I 
Human C Requirement for RDDP release from Xenotropic 
MuLV 
Virus treatment  3H-TMP incorporated 
pmol 
Fresh serum  2.17 
Heated serum  0.04 
C2-deficient serum  0.10 
C4-depleted serum  0.02 
CS-deficient serum  0.17 
Control  (NP-40)  3.73 
The ability of fresh serum to release RDDP from oncornaviruses was reduced 
or eliminated by removal of factor B, an essential component of the alternative 
pathway. Serum depleted of factor B released from 15 to 54% of the amount of 
enzyme released by fresh human serum in various studies. Higher release was 
obtained with immunochemical depletion than with heat depletion of factor B. 
For example, a serum immunochemically depleted of factor B released sufficient 
RDDP from feline  leukemia  virus to  incorporate  0.83 pmol of aH-TMP while 
serum depleted by heating released no RDDP. These values compare with 1.55 
pmol for fresh human serum. 
It was considered important to also examine depleted serum after reconstitu- 
tion  since  the  depletion  process may also reduce the  levels of other limiting 
components.  However,  our measurements  of RDDP release  by reconstituted 
sera were erratic  and  usually only partial  reconstitution  of ability to release 
RDDP was found despite the fact that in parallel studies the same reconstituted 
sera released large amounts of RNA from the viruses. For this reason we used 
only RNA release to measure the effectiveness of reconstitution.  Fig.  1 shows 
reconstitution by C4 of the ability of serum immunochemically depleted of C4 to 
release 3H-uridine from RaLV. The virus-associated radioactivity appeared as a 
single symmetrical peak located at a  density of 1.14 g/cm  3 after incubation of 
RaLV with C4-depleted human serum (center panel). After reconstitution with 
physiological amounts of C4,  the seru~n effectively released 3H-uridine  (lower 
panel).  Although  not shown,  the  virus was also concurrently  incubated  with 
buffer, heated human serum,  fresh feline serum, or fresh guinea pig serum in 
the  same  experiment.  In  each  instance  the  peak  of radioactivity  was  found 
between 1.14 and 1.15 g/cm  3 in a symmetrical distribution essentially identical 
to that found in the center panel of Fig.  1. Also in the same experiment,  serum 
depleted of factor B by heating released 24% of the 3H-uridine from RaLV while 
75%  release  was observed after reconstitution  with  physiological  amounts  of 
factor B.  The  above studies  indicate  that,  whereas  integrity  of the  classical 
pathway  is  an  absolute  requirement  for  lysis  of oncornaviruses  by human 
serum, factor B of the alternative pathway is also needed for maximal lysis. 
As anticipated from the above results, oncornaviruses efficiently activated the 
C system as shown by a reduction in C activity of fresh serum after incubation 
with oncornaviruses as shown in Table II. There was, however, no correlation 
between the  amount  of protein  added  and  the  extent  of C  consumption  by COOPER,  JENSEN,  WELSH,  AND  OLDSTONE  975 
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FIG.  1.  Equilibrium  sucrose  density  gradient  of RaLV  exposed  to  WHS serum  (upper 
panel),  C4-depleted (C4D) human serum (middle panel), and C4D human serum reconsti- 
tuted with C4 (lower panel).  RaLV, internally labeled with 3H-uridine, was reacted with 
serum, depleted serum, or reconstituted depleted serum, and analyzed by sucrose density 
gradient ultracentrifugation as described in the Materials and Methods.  The direction of 
sedimentation is to the left. The essential role of C4 for viral lysis is evident. 
oncornaviruses. C consumption was not caused by the presence of contaminat- 
ing viral or cellular RNA or DNA in the virus preparations, since C consump- 
tion by MLV was unaffected by the presence of high concentrations of RNase, 
DNase,  or both enzymes. Measurement of residual C  component levels after 
incubation of the MLV preparation obtained from the NCI with normal serum 
(89%  CHso depletion)  showed  a  pattern  of consumption  typical  of classical 
pathway activation with marked depletion of C2 and C4 activities (Fig. 2). 
Deposition of C Proteins on the Viral Surface.  The following approach was 
used to demonstrate the presence of C4 on the viral surface afLer incubation of 
MLV with whole human serum. MLV, surface labeled with 125I, was incubated 
with  normal  human  serum  (WHS)  or  C4-depleted  human  serum  and  then 
separated  from  unbound  serum  constituents  by  rate  zonal  sucrose  density 
gradient ultracentrifugation. A pool of fractions from the radioactive peak from 
the gradient representing l~SI-virus and bound serum proteins was then incu- 
bated with the IgG fraction of  an antiserum to C4 after which the mixtures were 
sedimented in a second set of  rate zonal sucrose density gradients. The sedimen- 
tation rate of  MLV previously incubated with serum was increased further after 
incubation with the IgG fraction of  antiserum to C4 as shown in Fig. 3, whereas 
the  sedimentation rate  of 12SI-MLV comparably incubated  with  C4-depleted 
serum  was  not  increased  after incubation with anti-C4.  These  studies thus 
demonstrate the presence of C4 on the viral surface. 
Antibody-Independent  Attachment  of Clq  to  MLV.  The  above  studies, 
which showed classical pathway involvement, when coupled with our earlier 
work indicating a lack of requirement for antibody, strongly suggest that MLV 976  COMPLEMENT  LYSIS  OF  RNA  TUMOR  VIRUSES 
TABLE  II 
Human C Consumption  by Oncornaviruses 
Viral preparation  Concentration  C consumption* 
mg/ml  % 
RaLV  1.01  30 
PRLV  0,36  36 
RLV  0.36  36 
MLV (FAN)  0,76  62 
MLV (179S)  2.68  70 
MLV (NCI)  1.25  89 
MLV (NCI) +  DNase$ 
MLV (NCI)  +  RNase$ 
MLV (NCI) +  DNase/RNase$ 
1.25  81 
1.25  82 
1.25  82 
* C consumption was assessed after  30 min of incubation at 37°C of a 
mixture of  equal volumes of  virus and human serum. 
The DNase and RNase final  concentrations in the reaction mixtures 
with virus  and human serum were 1.7 mg/ml and 2.3 mg/ml, respec- 
tively. 
directly activated the classical  pathway. This possibility  was explored in the 
following experiments. Two approaches were used to assess the ability  of iso- 
lated MLV  to interact with immunoglobulin-free Clq. First,  in the Clq devia- 
tion  test  illustrated  in Fig.  4, MLV  inhibited the binding of  Clq to EA in  a dose 
related manner,  a finding which strongly suggests binding of Clq to MLV. 50% 
inhibition occurred with  1 ~g of purified  MLV,  a  value which corresponds to 
approximately 4,700 molecules of Clq per virion.  Second,  mixtures of ~25I-Clq 
and MLV were sedimented in rate zonal sucrose density gradients to examine 
the possibility of binding of Clq to MLV. These studies clearly documented the 
direct attachment of Clq to MLV. It was possible to select ratios of reactants to 
maximize binding of Clq to MLV as shown in Fig. 5. In this study, virtually all 
of the Clq in the 125I-Clq-MLV mixture bound to MLV as it sedimented at a rate 
identical to that of 12SI-MLV which was sedimented in a  separate tube. In the 
absence of MLV, Clq was found at the top of the gradient  (Fig. 5). 
Antibody-Independent Activation of C1 by ML V.  The following experiments 
were designed to show that the interaction of Clq with MLV led to activation of 
macromolecular C1  and thus was responsible for activation of the classical C 
pathway. These studies employed precursor C1 reconstituted from highly puri- 
fied  immunoglobulin-free  human  Clq,  isolated  proenzyme  human  Clr,  and 
purified ~2SI-labeled proenzyme human Cls. After incubation of reconstituted C1 
with  MLV  the  following  were  added:  SDS,  urea,  and  reducing  agent.  The 
mixtures were analyzed by SDS-PAGE, sectioned, and analyzed for radioactiv- 
ity. Proenzyme Cls is known to consist of a single polypeptide chain with a mol 
wt of 87,000  daltons.  After activation,  which  is accomplished  by Clr,  Cls  is 
cleaved into two fragments of 59,000  and 28,000 daltons.  As depicted in Fig. 6, 
which represents a typical experiment, the mol wt of 125I-Cls was reduced from 
89,000 to 59,000 daltons after incubation with aggregated IgG or with MLV, thus 
documenting activation. As shown in the controls included in each run (Fig. 6) 
activation required the presence of the Clq subunit and thus was not explaina- 
ble by a direct effect of the MLV preparation on Clr or Cls. Three preparations COOPER~ JENSEN,  WELSH,  AND  OLDSTONE 
100 
977 
o_..,~  60 
CHso  Cl  C4  C2 C3  C5  C8  C9 
Fro. 2.  Pattern  of  consumption  of  C activity  in  normal serum after  incubation  with  MLV. 
WHS  was incubated with MLV  (NCI) after  which the remaining CHso and C component 
levels  were determined. The percentage of consumption was determined by subtraction 
from the values obtained from the control  of normal serum incubated with buffer.  The 
pattern of  consumption is  typical  of  classical  pathway activation. 
of MLV  examined in this manner in 15 experiments were able to activate 
reconstituted  C1. 
Discussion 
In  our  earlier  studies  we found  that  fresh  human serum, but  not  serum from  a 
number of other species  could lyse  and thus inactivate  oncornaviruses from 
several diverse  species.  Lysis  required an intact  source of C. The detailed 
analysis of the role  of the human C system in this  reaction  presented here 
indicates  that  the  classical  C pathway is  required  for  lysis  since  neither  C2-  nor 
C4-deficient sera were able to mediate lysis.  Lyric  ability  was restored on 
addition  of  the missing  component (Fig.  1).  The marked consumption of  C2 and 
C4 in serum treated  with MLV. also documents primary activation  of the 
classical  pathway (Fig.  2). Since the alternative  or properdin pathway, which 
also  possesses  cytolytic  activity,  was shown to  be functional  in the C2o and C4- 
deficient  sera,  it might be inferred  that the oncornaviruses examined do not 
effectively  activate  this  pathway. However, we also  regularly  observed a reduc- 
tion,  and on occasion  a complete loss,  in ability  to lyse  MLV  after  depletion  of 
factor  B from the serum. These findings  suggest that  factor  B and presumably 
the C3b-dependent feedback system are required for full  expression  of the 
cytolytic  potential  of  the serum. The feedback system, which requires  factor  B, 
factor  D, and C3b and  which becomes operative  after  generation of  C3b, leads  to 
additional  formation of  C3b  and  activation  of  late-reacting  C components. In  this 
context,  the system may be visualized  as amplifying an initial  relatively  minor 
degree of  C activation  and thus rendering it  biologically  significant. 
Classical  pathway activation  by oncornaviruses results  from direct  interac- 
tion  of the virus with Clq which leads in turn to activation of Clr and Cls, and 
thus of the C1 molecule. These conclusions stem from studies in which isolated 
MLV bound highly purified human Clq (Figs. 4 and 5). Both the Clq deviation 
test  and  sucrose  density  gradient  ultracentrifugation  studies  demonstrated 
binding of MLV to Clq mixtures. Although both types of studies indicated that 
saturation occurred between 5,000 and 8,000 molecules of Clq per virion, these 
levels must be considered as approximate because of uncertainty as to the exact 
concentration of viral particles in the MLV preparations. 978  COMPLEMENT  LYSIS  OF  RNA  TUMOR  VIRUSES 
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Fro.  3.  Rate zonal sucrose density gradient ultracentrifugation of MLV (surface labeled 
with 125I first incubated with WHS (upper panel) or C4-depleted (C4D) human serum (lower 
panel) and then with anti-C4 MLV. Solid lines denote the position of 1~I-MLV previously 
incubated with normal (upper panel) or C4-depleted (lower panel) sera while the dashed 
lines indicate the position of the comparable samples incubated with anti-C4. The ability of 
anti-C4  to  increase  the  sedimentation  rate  of  MLV  previously  incubated  with  serum 
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FZG. 4.  Reactivity of Clq with MLV as demonstrated by the Clq deviation test. MLV was 
incubated with ~25I-Clq after which EA were added. The percent of 125I-Clq binding to EA in 
the absence of MLV was 74% of the total added, as shown on the ordinate. The progressive 
inhibition by MLV of Clq binding to EA documents Clq binding to MLV. 
Several examples of substances able to interact with and precipitate Clq but 
which do not lead to activation of the C system have been reported.  We felt it 
important to rule out this type of interaction by demonstrating that the interac- 
tion of Clq with MLV led to C  activation.  The test system developed for this 
purpose  involved  activation  of proenzyme  macromolecular  C1  reconstituted 
from highly purified immunoglobulin-free human Clq and isolated proenzyme COOPER,  JENSEN,  WELSH,  AND  OLDSTONE 
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FIG.  5.  Rate zonal sucrose density gradient ultracentrifugation of an MLV-CZq mixture 
(upper panel),  ~2sI-Clq alone (middle panel),  and  ~2~I-MLV alone (lower panel),  izsI-Clq 
previously incubated with MLV (upper panel) sediments at the same rate as 12~I-MLV alone 
(lower panel), documenting the direct binding of Clq to MLV. 
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Clr and Cls. Activation of Cls in C1, which is accomplished by Clr, leads to 
cleavage of the single 89,000 dalton polypeptide chain of proenzyme Cls into 
59,000 and 28,000 dalton subunits. Three different preparations of MLV were 
found to  consistently activate  reconstituted C1  when examined in  this  test 
system (Fig.  6).  Control studies showed that MLV produced no activation on 
omission of Clq, a finding which not only demonstrates the Clq requirement but 
also rules out a contaminating cellular enzyme present in the MLV preparation 
as responsible for C1 activation. It is quite probable that the activation of C1 by 
MLV shown in the isolated system fully explains the activation of  the classical C 
pathway on addition of MLV to serum since the concentrations of C  lq, C lr, and 
Cls employed in the C1 activation test duplicate, except for a twofold reduction 
in Clq, the relationship between these components in serum. In addition MLV 
activates serum C in a concentration range similar to that employed in the C1 
activation test when the ratio of MLV to C1 is considered. 
Antibody is clearly not responsible for binding of Clq by MLV since Clq 
preparations lacking detectable immunoglobulin bound completely to MLV and 
triggered C1 activation (Fig. 5). These findings thus confirm our earlier conten- 
tion based on  multiple indirect lines of evidence that oncornaviral lysis by 
human serum does not require antibody (29, 30). Therefore, in this system, the 
Clq  molecule fulfills the  functional role of antibody since  it  subserves  the 
specific recognition function normally characteristic of  the antibody molecule. A 
direct recognition role for Clq, or antibody-independent  activation of the classi- 
cal  pathway has  also  been demonstrated for several other diverse systems. 
These include cardiac mitochondrial membranes (47), C-reactive protein-C poly- 
saccharide complexes (48), polynucleotides and nucleic acids (49, 50), lipid A of 
lipopolysaccharide (51), cholesterol-containing  liposomes (52), and heparin-prot- 
amine complexes (53). Curiously, at least two of the above systems, i.e., mite- 
chondrial membranes and C-reactive protein-C polysaccharide complexes are 980  COMPLEMENT  LYSIS  OF  RNA  TUMOR  VIRUSES 
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Fro. 6.  SDS-PAGE  analysis of C1 activation by MLV.  C1 was reconstituted by Clq, 
proenzyme Clr, and 1~SI-proenzyme  Cls  and incubated with 30 ~g  ofMLV  (NCI)  or  30 jag  of 
aggregated IgG. The mixtures were then subjected  to SDS-PAGE  analysis after  which the 
gels  were sectioned and radioactivity  measured. The mixture of  Clq, Clr, and Cls (upper 
left  panel) indicates  that the 125I-Cls  is  primarily in the 87,000 dalton single  chain proen- 
zyme form. This mixture, which represents proenzyme CI, is  capable of  being activated  by 
aggregated (Agg)  IgG (lower  left  panel)  or  MLV  (lower  right  panel) as  shown by  cleavage of 
the single  87,000  dalton polypeptide chain of  Cls into  a 59,000  dalton fragment (and also  a 
28,000 dalton fragment which is not radiolabeled).  MLV  does not possess the ability  to 
activate  C1 in the absence of  Clq (upper right panel). 
similar to the oncornaviral system in activating human but not guinea pig C. As 
is obvious from this diverse list of substances, multiple different mechanisms, in 
addition to the familiar interaction with the Fc region of immunoglobulins, may 
lead to Clq binding. These include charge attraction between Clq, one of the 
most cationic proteins of serum,  and  negatively charged molecules such as 
DNA, RNA, and acidic polynucleotides. Clq interaction with some of the sub- 
stances listed above is difficult to explain on this basis and it is probable that 
other unknown types of interactions of Clq with proteins, carbohydrates, and 
perhaps lipids occur. 
The  structural  features on  the  oncornaviral envelope  responsible  for  C1 
activation have not been addressed by this study. Several proteins have been 
found to be associated with the MuLV oncornaviral envelope including p12, p15, 
and gp70 (54). Any of these could potentially be involved in binding of Clq. 
Alternatively, it is possible that a polysaccharide or lipid constituent of the viral 
envelope acquired from the host cell membrane is responsible for Clq binding, a COOPER,  JENSEN,  WELSH,  AND  OLDSTONE  981 
not unreasonable possibility in view of Clq binding by certain polysaccharides 
and lipid-containing substances as noted above. In this context, it is of interest 
that cellular membranes of certain continuously growing lymphoid cells also 
directly activate  C  (55-57). Although  alternative pathway activation  is  in- 
volved, in these instances, our recent studies indicate that continuously  growing 
lymphoid cells also activate the classical pathway. Alternatively, direct activa- 
tion by cells may be  related to  the  surface expression of oncornaviruses in 
analogy to the direct activation reported here. In this regard, the ability to 
directly activate C was engendered in a cell line by oncornavirus infection (55). 
The biological relevance of the reported results is not clear at the present 
time, although one might speculate that the ability of human serum to inacti- 
vate oncornaviruses represents a natural defense mechanism operative in vivo 
which limits horizontal spread of oncornaviruses and also prevents expression of 
intact oncornaviruses by cells which may have become infected or which bear 
oncornavirus genomes. This interpretation is in accord with the frequent occur- 
rence of intact oncornaviruses in malignancies of many species including chick- 
ens, guinea pigs, rabbits, rats, and mice, whose C is unable to lyse oncornavi- 
ruses and with the rare expression of intact oncornaviruses in human malignan- 
cies. An apparent contradiction to this hypothesis is the occasional expression of 
oncornavirus during the  course of certain malignancies in rhesus monkeys. 
Since normal rhesus serum lyses oncornaviruses (30), an evaluation of the C 
status of monkeys expressing oncornaviruses is particularly indicated. It will 
also be of considerable interest to determined whether the disappearance of 
oncornaviruses from normal human and rhesus monkey placentas during ontog- 
eny (15) correlates with the development of cytolytic potential of the classical C 
system. Finally, a continuing evaluation of individuals, who have congenital or 
acquired deficiencies in components of the classical pathway, for oncornavirus 
expression, and development of malignancies is indicated in determining the in 
vivo relevance of these findings. 
Summary 
In earlier studies we found that human serum, but not serum from multiple 
other species, inactivated and lysed oncornaviruses from a number of diverse 
sources in the apparent absence of  antibody. A detailed analysis of  the role of  the 
human complement (C) system in mediating this lytic process indicates that 
human Clq interacts directly, in the absence of immunoglobulin, with oncorna- 
viruses. Binding of C1 via Clq in this manner leads to activation of Clr, Cls, 
and thus of the classical C pathway. Integrity of the classical pathway is an 
absolute requirement for lysis although activation of the alternative pathway 
considerably amplifies the amount of lysis obtained, possibly through involve- 
ment of  the C3b-dependent feedback mechanism. Activation of C is accompanied 
by deposition of C components on the viral surface and lysis on completion of the 
C reaction sequence. Thus in this system, the Clq subunit of C1 subserves a 
specific recognition function normally associated with antibody. This ability of 
human serum to inactivate oncornaviruses may represent a  natural defense 
mechanism operative in vivo which deters expression of intact oncornaviruses in 
human malignancies. 982  COMPLEMENT  LYSIS  OF  RNA  TUMOR  VIRUSES 
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